Targeted Therapy of Bronchiolitis Obliterans Syndrome



Status:Completed
Conditions:Bronchitis, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:6 - 99
Updated:10/6/2017
Start Date:June 2011
End Date:December 2015

Use our guide to learn which trials are right for you!

Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

This phase II trial studies how well giving fluticasone propionate, azithromycin, and
montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans
who previously underwent stem cell transplant. FAM may be an effective treatment for
bronchiolitis obliterans

PRIMARY OBJECTIVES:

I. To determine if the combination treatment of FAM administered in post hematopoietic cell
transplantation (HCT) recipients after the diagnosis of new onset bronchiolitis obliterans
syndrome (BOS) can decrease the rate of treatment failure relative to an estimated historical
rate of 40% using current therapies.

SECONDARY OBJECTIVES:

I. To confirm the safety profile of FAM.

II. To describe the effect on other standard pulmonary function test parameters: forced
expiratory flow at 25%-75% of forced vital capacity (FVC) (FEF25-75), residual volume (RV),
diffusion capacity of carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1)/FVC
ratio and FEV1/slow vital capacity (SVC) ratio with FAM treatment.

III. To determine the change in molecular markers of inflammation and fibrosis in the blood
with FAM treatment.

IV. To assess the impact of FAM on other chronic graft-versus-host disease (GVHD)
manifestations.

V. To assess the impact of FAM on functional status, and health-related quality of life
(HRQOL).

VI. To describe changes in steroid dosing.

OUTLINE:

Patients receive fluticasone propionate inhaled orally (PO) twice daily (BID), azithromycin
PO 3 days a week, and montelukast sodium PO once daily (QD). Treatment continues for 6 months
in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 6 months.

Inclusion Criteria:

- Diagnosis of BOS after HCT within the 6 months before study enrollment; for this
study, BOS is defined as:

- Forced expiratory volume in 1 second (FEV1) < 75% of the predicted normal and
FEV1 to slow or inspiratory vital capacity ratio (FEV1/SVC or FEV1/IVC) =< 0.7,
both measured before and after administration of bronchodilator OR

- Pathologic diagnosis of BOS demonstrated by lung biopsy

- The baseline absolute FEV1 must be >= 10% lower than the pre-transplant absolute FEV1
as defined by the pre-transplant FEV1 minus the baseline FEV1, both measured before
administration of a bronchodilator

- Participant (or parent/guardian) has the ability to understand and willingness to sign
a written consent document

Exclusion Criteria:

- Recurrent or progressive malignancy requiring anticancer treatment

- Known history of allergy to or intolerance of montelukast, zafirlukast, azithromycin,
erythromycin, or clarithromycin

- Pregnancy or nursing; all females of childbearing potential must have a negative serum
or urine pregnancy test < 7 days before study drug administration

- Transaminases > 5 X upper limit of normal (ULN)

- Total bilirubin > 3 X ULN

- Chronic treatment with any inhaled steroid for > 1 month in the past three months

- Treatment with montelukast or zafirlukast for > 1 month during the past three months

- Treatment with prednisone at > 1.2 mg/kg/day (or equivalent steroid)

- Treatment with rifampin or phenobarbital, aspirin at doses > 325 mg/day, or ibuprofen
at doses > 1200 mg/day

- Treatment with any Food and Drug Administration (FDA) non approved study medication
within the past 4 weeks; off-label treatment with an FDA-approved medication is
allowed

- Chronic oxygen therapy

- Evidence of any viral, bacterial or fungal infection involving the lung and not
responding to appropriate treatment

- Clinical asthma (variable and recurring symptoms of airflow obstruction and bronchial
hyper-responsiveness)

- Any condition that, in the opinion of the enrolling investigator, would interfere with
the subject's ability to comply with the study requirements

- Uncontrolled substance abuse or psychiatric disorder

- Inability to perform pulmonary function tests (PFT) reliably, as determined by the
enrolling investigator or PFT lab

- Life expectancy < 6 months at the time of enrollment as judged by the enrolling
investigator

- Baseline post-bronchodilator FEV1 < 20% of predicted normal before or after albuterol
We found this trial at
11
sites
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
612-624-2620
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
206-667-4584
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium The Fred Hutchinson/University of Washington Cancer...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
2201 West End Ave
Nashville, Tennessee 37232
(615) 322-7311
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
5777 E Mayo Blvd
Scottsdale, Arizona 85259
(480) 515-6296
Mayo Clinic Scottsdale Mayo Clinic Arizona was the second Mayo practice to be established outside...
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials